All articles by Staff Writer
Staff Writer
India’s G20 Presidency Drives Global Digital Health Initiative for Accessible and Equitable Global Healthcare
The spotlight is poised to shine on India as the G20 Health Minister’s Meeting, under India’s G20 Presidency, kicks off from 17 to 19 August 2023 in Gandhinagar, Gujarat, India. The prestigious gathering promises impactful discussions on global health collaboration and the launch of a Global Initiative on Digital Health.
Heart Failure start-up, Acorai, embarks on the next vital stage towards regulatory approval
Today, Acorai, a start-up medical device manufacturer from Sweden, has announced the initiation of a global clinical trial with the enrollment of its first patient in London, UK. Acorai was designated as a breakthrough device by the US FDA in August 2023 and they aim to submit their heart monitor for regulatory approval to the FDA and CE-marking in 2024.
Teleflex secures expanded FDA approval for QuikClot Control+ haemostatic device
The FDA approval expands the use of QuikClot Control+ haemostatic device to include mild and moderate bleeding in cardiac surgical procedures and bone surface bleeding following a sternotomy, including patients on anticoagulation or antiplatelet medication
Masimo SedLine Psi improves brain monitoring for certain sedated patients in study
According to the company, Masimo PSi, which is a SedLine parameter from electroencephalographic data, was found statistically and significantly related to dexmedetomidine dosage
Abbott secures FDA approval for Alinity H-Series haematology system
The Alinity h-series system includes an integrated slide maker and stainer Alinity hs, and an automated haematology analyser Alinity hq, which deploys the advanced MAPSS technology to better identify various blood cells
First Patient Dosed in IPAX-2 Study of TLX101 Brain Cancer Therapy Candidate in Patients with Newly Diagnosed Glioblastoma
Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that a first patient has been dosed in a Phase I study of the Company’s investigational therapy TLX101 (4-L-[131I] iodo-phenylalanine, or 131I-IPA) in combination with post-surgical standard of care treatment in patients with newly diagnosed glioblastoma, the most common and aggressive form of primary brain cancer.
SEKISUI Diagnostics unveils OSOM Covid-19 antigen home test
OSOM Covid-19 antigen home test is a lateral flow immunoassay tool, designed for the qualitative identification of SARS-CoV-2 virus nucleocapsid protein antigen
Yodaplus: Shaping the Future of Industries with Powerful AI Integration
Leveraging artificial intelligence, Mumbai-based IT services firm Yodaplus is catalyzing industry transformations, from nutraceuticals to retail, by streamlining business operations and boosting decision-making capabilities.
FDA Clears CorNeat EverPatch, World’s First Non-degradable, Synthetic Tissue Substitute for Ophthalmic Surgery
CorNeat Vision’s EverPatch Utilizes EverMatrix™, A Novel Material Technology Able to Integrate with Surrounding Tissue
FDA Clears Numares Health Cardiovascular Diagnostic Test and Core Technology Platform
The US Food and Drug Administration has cleared a Numares Health test, the AXINON® LDL-p Test System, as a new tool physicians can use to measure lipoproteins for patients at risk for cardiovascular disease. Currently, Numares is the only company in the US selling an FDA-cleared NMR test.